Profile data is unavailable for this security.
About the company
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
- Revenue in USD (TTM)314.00k
- Net income in USD-40.23m
- Incorporated2020
- Employees83.00
- LocationATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
- Phone+49 8 921539035
- Fax+49 89 215390351
- Websitehttps://atai.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc | 433.14m | 4.95m | 323.48m | 862.00 | 66.38 | 1.15 | 15.93 | 0.7468 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 324.36m | 7.00 | -- | 1.20 | -- | 280.59 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 324.51m | 100.00 | -- | 16.42 | -- | 63.33 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.96m | 324.65m | 79.00 | -- | 1.12 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 325.02m | 40.00 | -- | 2.33 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 331.84m | 75.00 | -- | 0.5921 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Caribou Biosciences Inc | 34.48m | -102.07m | 336.89m | 158.00 | -- | 0.8955 | -- | 9.77 | -1.45 | -1.45 | 0.4675 | 4.17 | 0.0856 | -- | 17.14 | 218,208.90 | -25.33 | -- | -27.24 | -- | -- | -- | -296.05 | -- | -- | -19,343.17 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| ATAI Life Sciences NV | 314.00k | -40.23m | 340.35m | 83.00 | -- | 1.40 | -- | 1,083.93 | -0.2845 | -0.2845 | 0.0019 | 1.46 | 0.001 | -- | 0.0438 | 3,783.13 | -13.46 | -- | -14.59 | -- | -- | -- | -12,835.35 | -- | -- | -169.33 | 0.0682 | -- | 34.76 | -- | 73.60 | -- | -- | -- |
| Cerus Corp | 186.80m | -37.49m | 342.05m | 288.00 | -- | 6.37 | -- | 1.83 | -0.2086 | -0.2086 | 1.04 | 0.2905 | 0.8984 | 2.03 | 5.34 | 648,600.70 | -18.11 | -25.99 | -32.81 | -40.62 | 62.54 | 61.90 | -20.15 | -35.81 | 1.55 | -2.91 | 0.5989 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Jasper Therapeutics Inc | 0.00 | -64.47m | 343.50m | 45.00 | -- | 3.24 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 345.73m | 163.00 | -- | 1.39 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| MeiraGTx Holdings PLC | 14.02m | -84.03m | 345.97m | 419.00 | -- | 2.48 | -- | 24.68 | -1.58 | -1.58 | 0.2483 | 2.17 | 0.0435 | -- | 0.8908 | 33,453.46 | -26.06 | -26.40 | -33.89 | -32.66 | -- | -- | -599.47 | -420.70 | -- | -91.62 | 0.3429 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 347.50m | 302.00 | -- | 1.73 | -- | 2.26 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Precigen Inc | 6.23m | -95.90m | 348.34m | 202.00 | -- | 2.90 | -- | 55.96 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 357.24m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Data as of May 08 2024. Currency figures normalised to ATAI Life Sciences NV's reporting currency: US Dollar USD
4.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2023 | 1.72m | 1.04% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.34m | 0.80% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 868.42k | 0.52% |
| Marshall Wace LLPas of 31 Dec 2023 | 775.89k | 0.47% |
| Millennium Management LLCas of 31 Dec 2023 | 760.76k | 0.46% |
| Brown University Investment Officeas of 31 Dec 2023 | 718.50k | 0.43% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 552.42k | 0.33% |
| BlackRock Advisors (UK) Ltd.as of 31 Dec 2023 | 489.39k | 0.30% |
| Citadel Advisors LLCas of 31 Dec 2023 | 426.11k | 0.26% |
| Two Sigma Investments LPas of 31 Dec 2023 | 415.74k | 0.25% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
